viewRedx Pharma PLC

Redx Pharma: Developing treatments for cancer and fibrosis


  • Cancer drug in the clinic 
  • Promising fibrosis treatments targeting large markets
researcher at microscope

Quick facts: Redx Pharma PLC

Price: 15 GBX

Market: AIM
Market Cap: £28.5 m


What the company does 

Redx Pharma Plc (LON:REDX) is an early-stage drug developer that is bringing through treatments for cancer and fibrosis.

Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors. They work by dialling down the Porcupine protein, which is the control switch for the Wnt pathway – known to be heavily involved in cell growth and division. Now, not all cancers are driven by the Wnt pathway, but the hope is that RXC004 will inhibit the growth of those which are.

Interestingly, there’s a growing bank of research that suggests Porcupine inhibitors may also be very effective in tandem with checkpoint inhibitors such as anti-PD-1s, which lower or break cancer’s defence against the body’s immune system. That’s why Redx plans to assess the drug in combination with a checkpoint inhibitor further down the line, something Swiss giant Novartis is doing with its Porcupine inhibitors.

In parallel it is developing potential fibrosis treatments. RXC006 is designed to tackle a condition called idiopathic pulmonary fibrosis (IPF), a type of chronic lung disease. ROCK2 has been developed to treat non-alcoholic liver disease, while it is also targeting Crohn’s Disease-related fibrosis.


After a false start, Redx is resuming its phase I clinical trial. The trial is split in two: phases Ia and Ib. The former is focused on finding the safest most effective dose, while the latter will seek efficacy data.  The phase Ia will take place over the next 12-18 months, working with advanced cancer patients. The lead investigator is Dr Natalie Cook, of the Christie Hospital, Manchester. The other centres are The Marsden and Guys (London), Oxford and Newcastle.

Value kickers

  • Second fibrosis drug candidate RXC007 to start trials in 2021

  • Fibrosis treatments target significant commercial markets

  • Phase 1-ready idiopathic pulmonary fibrosis candidate ready to enter the clinic in 2020


What the boss says: Lisa Anson, chief executive

"We look forward to taking RXC007 into clinical trials in the first half of 2021. Redx is pleased to be progressing the development of this exciting drug candidate that selectively inhibits ROCK2 as a potential treatment for multiple fibrotic diseases."

"This is a challenging area of chemistry and the Redx team is proud to deliver another successful drug candidate."



Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma PLC named herein, including the promotion by the Company of Redx Pharma PLC in any Content on the Site, the Company receives from...



Morning Report: FTSE 100 rallies as Italians ban short selling

Headlines from the Proactive UK newsroom. The FTSE 100 rallied this morning even though Asian markets suffered more pain overnight.  London’s blue chip index opened around 157 points higher at 5,395 after giving up 639 points yesterday. Italy has introduced a temporary ban on...

3 weeks, 2 days ago

2 min read